Interpace Biosciences, Inc.
IDXG
$0.95
$0.077.35%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -5.16% | -19.83% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.16% | -19.83% | |||
| Cost of Revenue | -16.15% | -4.56% | |||
| Gross Profit | 3.09% | -28.41% | |||
| SG&A Expenses | -25.61% | 3.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -21.54% | 0.14% | |||
| Operating Income | 344.66% | -125.59% | |||
| Income Before Tax | 287.62% | -130.08% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 289.68% | -130.39% | |||
| Earnings from Discontinued Operations | 6.54% | 0.00% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 242.34% | -138.86% | |||
| EBIT | 344.66% | -125.59% | |||
| EBITDA | 442.23% | -119.07% | |||
| EPS Basic | 242.29% | -138.84% | |||
| Normalized Basic EPS | 287.52% | -130.05% | |||
| EPS Diluted | 125.16% | -357.93% | |||
| Normalized Diluted EPS | 130.01% | -288.25% | |||
| Average Basic Shares Outstanding | 0.05% | 0.07% | |||
| Average Diluted Shares Outstanding | 526.16% | -84.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||